Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Halozyme Therapeutics's current 3-Year Share Buyback Ratio was 4.50%.
The historical rank and industry rank for Halozyme Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
HALO'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4 Med: -4.4 Max: 4.5
Current: 4.5
During the past 13 years, Halozyme Therapeutics's highest 3-Year Share Buyback Ratio was 4.50%. The lowest was -20.40%. And the median was -4.40%.
HALO's 3-Year Share Buyback Ratio is ranked better than 98.48% of 1184
companies
in the Biotechnology industry
Industry Median: -11.6
vs HALO: 4.50
Halozyme Therapeutics (NAS:HALO) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Halozyme Therapeutics 3-Year Share Buyback Ratio Related Terms
HALO vs ARWR, CORT, MDGL: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's 3-Year Share Buyback Ratio falls into.
Halozyme Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 4.50 mean?
Halozyme Therapeutics (HALO) has a 3-Year Share Buyback Ratio of 4.50 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Halozyme Therapeutics and its competitors. According to the industry distribution chart, Halozyme Therapeutics ranks #18 out of 1184 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Halozyme Therapeutics' 3-Year Share Buyback Ratio too high?
Halozyme Therapeutics' current 3-Year Share Buyback Ratio is 4.50. Based on the distribution chart, Halozyme Therapeutics ranks #18 out of 1184 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' 3-Year Share Buyback Ratio compare to ARWR and CORT?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #18 out of 1184 companies for 3-Year Share Buyback Ratio. This places Halozyme Therapeutics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current 3-Year Share Buyback Ratio is 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Overvalued. The stock's GF Value™ is $100.30, compared to a current price of $112.63 — trading 12.3% above its estimated fair value. The current 3-Year Share Buyback Ratio is 4.50. Halozyme Therapeutics' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current 3-Year Share Buyback Ratio is 4.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of $112.63 is trading 12.3% above its estimated GF Value™ of $100.30.
GuruFocus considers Halozyme Therapeutics to be Modestly Overvalued.
Key valuation signals for HALO:
3-Year Share Buyback Ratio: 4.50
GF Value™: $100.30 vs. price of $112.63 (12.3% above fair value)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
89GF Score
Get the complete analysis for HALO
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
